Briacell Therapeutics
BCTX
16 hedge funds and large institutions have $1.62M invested in Briacell Therapeutics in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
2,242% more capital invested
Capital invested by funds: $69.2K → $1.62M (+$1.55M)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
23% more funds holding
Funds holding: 13 → 16 (+3)
4.82% more ownership
Funds ownership: 0.51% → 5.34% (+4.8%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCC
Cable Car Capital
San Francisco,
California
|
+$1.01M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$344K |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$303K |
| 4 |
LCM
LuminArx Capital Management
New York
|
+$69.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$50.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
-$28.4K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$3.49K |
| 3 |
Morgan Stanley
New York
|
-$2.23K |
| 4 |
SSA
SSA Swiss Advisors
Zurich,
|
-$264 |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$251 |
BCTX Hedge Fund Activity: Q1 2026 in Review
16 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q1 2026, worth a combined $1.62M — up 2,242% from $69.2K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BCTX positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Cable Car Capital, opening a new position worth an estimated $1.01M. The largest seller was Flagship Harbor Advisors, exiting entirely with an estimated $28.4K sold.
- 16 institutional investors held Briacell Therapeutics (BCTX) as of Q1 2026, up from 13 in Q4 2025.
- Funds reported $1.62M of Briacell Therapeutics stock for Q1 2026, up 2,242% quarter-over-quarter.
- 6 funds opened new Briacell Therapeutics positions in Q1 2026 and 3 closed out, a net change of +3 holders.
- The largest Briacell Therapeutics buyer in Q1 2026 was Cable Car Capital, an estimated $1.01M added.
- The largest Briacell Therapeutics seller in Q1 2026 was Flagship Harbor Advisors, an estimated $28.4K sold.
Based on aggregated 13F filings for Q1 2026.